Selpercatinib

Chemical formula: C₂₉H₃₁N₇O₃  Molecular mass: 525.613 g/mol 

Therapeutic indications

Selpercatinib is indicated for:

RET fusion-positive non-small cell lung cancer

Population group: only adults (18 years old or older)

Selpercatinib as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

RET fusion-positive thyroid cancer

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Selpercatinib as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

RET-mutant medullary thyroid cancer

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Selpercatinib as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Advanced RET fusion-positive solid tumours

Population group: only adults (18 years old or older)

Selpercatinib as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Selpercatinib is contraindicated in the following cases:

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.